1628805-46-8Relevant articles and documents
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Young Shin,Levell, Julian R.,Liu, Gang,Caferro, Thomas,Sutton, James,Shafer, Cynthia M.,Costales, Abran,Manning, James R.,Zhao, Qian,Sendzik, Martin,Shultz, Michael,Chenail, Gregg,Dooley, Julia,Villalba, Brian,Farsidjani, Ali,Chen, Jinyun,Kulathila, Raviraj,Xie, Xiaoling,Dodd, Stephanie,Gould, Ty,Liang, Guiqing,Heimbach, Tycho,Slocum, Kelly,Firestone, Brant,Pu, Minying,Pagliarini, Raymond,Growney, Joseph D.
, p. 1116 - 1121 (2017/10/18)
Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg132. Having identified an allosteric, induced pocket of IDH1R132H, we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors for in vivo modulation of 2-HG production and potential brain penetration. We report here optimization efforts toward the identification of clinical candidate IDH305 (13), a potent and selective mutant IDH1 inhibitor that has demonstrated brain exposure in rodents. Preclinical characterization of this compound exhibited in vivo correlation of 2-HG reduction and efficacy in a patient-derived IDH1 mutant xenograft tumor model. IDH305 (13) has progressed into human clinical trials for the treatment of cancers with IDH1 mutation.
